Jiang Lianxiang, Hu Meizhu, Lu Yan, Cao Ya, Chang Yan, Dai Zeping
Department of Anaesthesiology, Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China.
Department of Anaesthesiology, Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China.
J Clin Anesth. 2017 Aug;40:25-32. doi: 10.1016/j.jclinane.2017.04.003. Epub 2017 Apr 17.
Intracranial lesions, trauma or surgery-related damage activate immune inflammation and neuroendocrine responses, causing ischemic brain injury. Studies have shown that inflammatory cascade mediated by neuroendocrine hormones and proinflammatory mediators is implicated in the pathophysiology of ischemic brain injury. Alpha2-adrenoceptor agonists, dexmedetomidine, is widely used as neuroprotectants in anesthesia practice. However, it is still lack of a comprehensive meta-analysis to evaluate the neuroprotection of dexmedetomidine against ischemic brain injury via suppressing these two physiological responses.
Searched the Cochrane Library, Pub-Med, EMBASE, EBSCO, Ovid, Chinese biological and medical database (CBM). Related literatures published in English or Chinese before January 2017 were enrolled. We assessed the quality of eligible studies and synthesized predefined outcomes with a random-effects model or fixed-effects model.
Nineteen Randomized Controlled Trials including 879 patients were included. Findings for meta-analysis of various outcomes were summarised. Primary results shown that compared with placebo, dexmedetomidine reduced a surge of TNF-α [SMD=-2.34, 95%CI (-3.25, -1.44)], IL-6 [SMD=-2.44, 95%CI (-3.40, -1.47)], S100-β [SMD=-2.73, 95%CI (-3.65, -1.82)], NSE [SMD=-1.69, 95%CI (-2.77, -0.61)], cortisol [SMD=-2.48, 95%CI (-3.38, -1.58)] and glucose [SMD=-1.44, 95%CI (-1.85, -1.04)]; maintained the level of SOD [SMD=1.36, 95%CI (0.62, 2.10)]; decreased the rise in CRP level at postoperative one day. In response to stress reaction, dexmedetomidine attenuated the stress-related increasing of MAP, HR and intracranial pressure without significant effects on cerebral oxygen metabolism.
Alpha2-adrenoceptor agonists, dexmedetomidine, could reduce the release of inflammatory mediators and neuroendocrine hormones as well as maintain intracranial homoeostasis, alleviating ischemic brain injury and exerting an effect on brain protection.
颅内病变、创伤或手术相关损伤会激活免疫炎症和神经内分泌反应,导致缺血性脑损伤。研究表明,由神经内分泌激素和促炎介质介导的炎症级联反应与缺血性脑损伤的病理生理学有关。α2肾上腺素能受体激动剂右美托咪定在麻醉实践中被广泛用作神经保护剂。然而,目前仍缺乏一项全面的荟萃分析来评估右美托咪定通过抑制这两种生理反应对缺血性脑损伤的神经保护作用。
检索Cochrane图书馆、Pub-Med、EMBASE、EBSCO、Ovid、中国生物医学数据库(CBM)。纳入2017年1月之前发表的英文或中文相关文献。我们评估了符合条件的研究的质量,并使用随机效应模型或固定效应模型综合预定义的结果。
纳入了19项随机对照试验,共879例患者。总结了各种结果的荟萃分析结果。主要结果显示,与安慰剂相比,右美托咪定降低了TNF-α[标准化均数差(SMD)=-2.34,95%置信区间(CI)(-3.25,-1.44)]、IL-6[SMD=-2.44,95%CI(-3.40,-1.47)]、S100-β[SMD=-2.73,95%CI(-3.65,-1.82)]、NSE[SMD=-1.69,95%CI(-2.77,-0.61)]、皮质醇[SMD=-2.48,95%CI(-3.38,-1.58)]和血糖[SMD=-1.44,95%CI(-1.85,-1.04)]的激增;维持了SOD水平[SMD=1.36,95%CI(0.62,2.10)];降低了术后一天CRP水平的升高。在应激反应方面,右美托咪定减弱了与应激相关的平均动脉压、心率和颅内压的升高,而对脑氧代谢无显著影响。
α2肾上腺素能受体激动剂右美托咪定可减少炎症介质和神经内分泌激素的释放,并维持颅内稳态,减轻缺血性脑损伤,发挥脑保护作用。